Biora Therapeutics Inc. (BIOR) NASDAQ
$0.62 0.02 (2.69%)
Market Cap: $21.51M
As of 04/19/24 03:57 PM EDT. Market closed.
Biora Therapeutics Inc. (BIOR)
NASDAQ
$0.62
0.02 (2.69%)
Market Cap: $21.51M
As of 04/19/24 03:57 PM EDT. Market closed.
Add to Portfolio
progenity helps patients and their families prepare for life, with medically relevant health information starting before conception, through pregnancy, childhood, and adulthood. using our highly-complex molecular diagnostic testing, healthcare providers can access the most advanced genomic technology to guide patient care at critical life ... read more
progenity helps patients and their families prepare for life, with medically relevant health information starting before conception, through pregnancy, childhood, and adulthood. using our highly-complex molecular diagnostic testing, healthcare providers can access the most advanced genomic technology to guide patient care at critical life stages. read less
COMPANY PROFILE
Sector
Industry
CEO
Harry Stylli
Full Time Employees
157
Sector
Industry
CEO
Harry Stylli
Full Time Employees
157
Address
4330 La Jolla Village Dr Ste 200, California, San Diego, 92122.
PRICE CHART FOR BIORA THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$0.61
Previous Close
$0.60
Days Range
$0.58 - $0.66
52 week range
$0.59 - $6.70
Volume
104,433
Avg. Volume (30 days)
639,549
Market Cap
$21.51M
Dividend Yield
-
P/E
(0.17)
Shares Outstanding
35,883,843
Open
$0.61
Previous Close
$0.60
Days Range
$0.58 - $0.66
52 week range
$0.59 - $6.70
Volume
104,433
Avg. Volume (30 days)
639,549
Market Cap
$21.51M
Dividend Yield
-
P/E
(0.17)
Shares Outstanding
35,883,843
FINANCIAL STATEMENTS FOR BIORA THERAPEUTICS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR BIORA THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| NEUMANN CLARKE | See Remarks | Aug 15, 2023 | Option Exercise | $3.14 | 36,183 | 113,615 | 52,018 | Aug 17, 2023, 04:27 PM |
| dEsparbes Eric | Chief Financial Officer | Aug 15, 2023 | Option Exercise | $3.14 | 40,022 | 125,669 | 59,012 | Aug 17, 2023, 04:22 PM |
| MOHANTY ADITYA P. | Chief Executive Officer | Aug 15, 2023 | Option Exercise | $3.14 | 117,881 | 370,146 | 161,042 | Aug 17, 2023, 04:21 PM |
| dEsparbes Eric | Chief Financial Officer | May 15, 2023 | Option Exercise | $3.35 | 2,807 | 9,403 | 99,034 | May 17, 2023, 04:56 PM |
| NEUMANN CLARKE | See Remarks | May 15, 2023 | Option Exercise | $3.35 | 2,368 | 7,933 | 88,201 | May 17, 2023, 04:55 PM |
| MOHANTY ADITYA P. | Chief Executive Officer | May 15, 2023 | Option Exercise | $3.35 | 11,249 | 37,684 | 278,923 | May 17, 2023, 04:54 PM |
| NEUMANN CLARKE | See Remarks | Mar 15, 2023 | Option Exercise | $2.56 | 10,683 | 27,348 | 90,569 | Mar 17, 2023, 09:21 PM |
| MOHANTY ADITYA P. | Chief Executive Officer | Mar 15, 2023 | Option Exercise | $2.56 | 22,252 | 56,965 | 290,172 | Mar 17, 2023, 09:18 PM |
| dEsparbes Eric | Chief Financial Officer | Mar 15, 2023 | Option Exercise | $2.56 | 11,216 | 28,713 | 101,841 | Mar 17, 2023, 09:16 PM |
| NEUMANN CLARKE | See Remarks | Feb 15, 2023 | Option Exercise | $3.46 | 84 | 291 | 21,618 | Feb 17, 2023, 04:15 PM |
| dEsparbes Eric | Chief Financial Officer | Feb 15, 2023 | Option Exercise | $3.46 | 269 | 931 | 28,140 | Feb 17, 2023, 04:15 PM |
| NEUMANN CLARKE | See Remarks | Nov 15, 2022 | Option Exercise | $0.27 | 4,529 | 1,223 | 542,398 | Nov 16, 2022, 09:49 PM |
| MOHANTY ADITYA P. | Chief Executive Officer | Nov 15, 2022 | Option Exercise | $0.27 | 175,071 | 47,269 | 2,799,858 | Nov 16, 2022, 09:48 PM |
| dEsparbes Eric | Chief Financial Officer | Nov 15, 2022 | Option Exercise | $0.27 | 5,194 | 1,402 | 710,122 | Nov 16, 2022, 09:48 PM |
| NEUMANN CLARKE | See Remarks | Aug 15, 2022 | Option Exercise | $1.04 | 1,355 | 1,409 | 546,927 | Aug 16, 2022, 06:02 PM |
| dEsparbes Eric | Chief Financial Officer | Aug 15, 2022 | Option Exercise | $1.04 | 5,952 | 6,190 | 708,429 | Aug 16, 2022, 05:58 PM |
| Sarna Surbhi | Director | Jul 05, 2022 | Sale | $0.61 | 7,517 | 4,585 | 148,774 | Jul 05, 2022, 06:48 PM |
| NEUMANN CLARKE | See Remarks | May 15, 2022 | Option Exercise | $0.75 | 8,305 | 6,229 | 308,320 | May 17, 2022, 05:27 PM |
| dEsparbes Eric | Chief Financial Officer | May 15, 2022 | Option Exercise | $0.75 | 10,387 | 7,790 | 412,784 | May 17, 2022, 05:18 PM |
| dEsparbes Eric | Chief Financial Officer | Feb 15, 2022 | Option Exercise | $1.90 | 4,919 | 9,346 | 191,478 | Feb 17, 2022, 04:05 PM |
| Hashemi Hutan | Chief Compliance Officer | Feb 15, 2022 | Option Exercise | $1.90 | 187 | 355 | 28,495 | Feb 17, 2022, 04:05 PM |
| NEUMANN CLARKE | See Remarks | Feb 15, 2022 | Option Exercise | $1.90 | 1,716 | 3,260 | 131,782 | Feb 17, 2022, 04:05 PM |
| NEUMANN CLARKE | See Remarks | Nov 15, 2021 | Option Exercise | $3.47 | 752 | 2,609 | 133,498 | Nov 17, 2021, 04:05 PM |
| Hashemi Hutan | Chief Compliance Officer | Nov 15, 2021 | Option Exercise | $3.47 | 645 | 2,238 | 28,682 | Nov 17, 2021, 04:05 PM |
| Cooper Matthew T | General Manager, Diagnostics | Nov 15, 2021 | Option Exercise | $3.47 | 700 | 2,429 | 134,039 | Nov 17, 2021, 04:05 PM |
| Silvestry Damon | See Remarks | Nov 15, 2021 | Option Exercise | $3.47 | 4,566 | 15,844 | 291,499 | Nov 17, 2021, 04:05 PM |
| NEUMANN CLARKE | See Remarks | Aug 15, 2021 | Option Exercise | $1.66 | 2,336 | 3,878 | 134,250 | Aug 17, 2021, 04:03 PM |
| Silvestry Damon | See Remarks | Aug 15, 2021 | Option Exercise | $1.66 | 1,478 | 2,453 | 289,178 | Aug 17, 2021, 04:03 PM |
| Stylli Harry | Chairman & CEO | Aug 15, 2021 | Option Exercise | $1.66 | 10,335 | 17,156 | 14,816,522 | Aug 17, 2021, 04:03 PM |
| Hashemi Hutan | Chief Compliance Officer | Aug 15, 2021 | Option Exercise | $1.66 | 158 | 262 | 22,440 | Aug 17, 2021, 04:01 PM |
| dEsparbes Eric | Chief Financial Officer | Aug 15, 2021 | Option Exercise | $1.66 | 5,718 | 9,492 | 196,397 | Aug 17, 2021, 04:00 PM |
| Cooper Matthew T | Chief Scientific Officer | Aug 15, 2021 | Option Exercise | $1.66 | 560 | 930 | 127,852 | Aug 17, 2021, 04:00 PM |
| Seelye Troy | Chief Information Officer | Aug 06, 2021 | Option Exercise | $1.94 | 23,673 | 45,926 | 59,756 | Aug 09, 2021, 09:19 PM |
| Athyrium Opportunities Fund (A) LP | 10% Owner | Jun 01, 2021 | Buy | $2.86 | 1,268,115 | 3,626,809 | 28,299,741 | Jun 03, 2021, 04:46 PM |
| Seelye Troy | Chief Information Officer | May 15, 2021 | Option Exercise | $2.36 | 1,925 | 4,543 | 83,429 | May 17, 2021, 08:46 PM |
| Hashemi Hutan | Chief Compliance Officer | May 15, 2021 | Option Exercise | $2.36 | 69 | 163 | 22,598 | May 17, 2021, 08:44 PM |
| Silvestry Damon | Chief Operating Officer | Apr 15, 2021 | Option Exercise | $3.41 | 3,681 | 12,552 | 290,656 | Apr 19, 2021, 09:38 PM |
| dEsparbes Eric | Chief Financial Officer | Apr 15, 2021 | Option Exercise | $3.41 | 13,690 | 46,683 | 202,115 | Apr 19, 2021, 09:32 PM |
| Shihabi Sami | Chief Commercial Officer | Mar 04, 2021 | Option Exercise | $4.05 | 2,623 | 10,623 | 35,062 | Mar 08, 2021, 05:20 PM |
| NEUMANN CLARKE | General Counsel and Secretary | Mar 04, 2021 | Option Exercise | $4.05 | 1,564 | 6,334 | 50,735 | Mar 08, 2021, 05:17 PM |
| Gianakopoulos George | Senior Vice President of Sales | Mar 04, 2021 | Option Exercise | $4.05 | 490 | 1,985 | 21,789 | Mar 08, 2021, 05:17 PM |
| Cooper Matthew T | Chief Scientific Officer | Mar 04, 2021 | Option Exercise | $4.05 | 1,609 | 6,516 | 49,352 | Mar 08, 2021, 05:16 PM |
| dEsparbes Eric | Chief Financial Officer | Mar 04, 2021 | Option Exercise | $4.05 | 1,608 | 6,512 | 92,423 | Mar 08, 2021, 05:14 PM |
| Stylli Harry | Chairman & CEO | Feb 15, 2021 | Option Exercise | $5.60 | 11,287 | 63,207 | 14,596,972 | Feb 17, 2021, 05:23 PM |
| Shihabi Sami | Chief Commercial Officer | Feb 15, 2021 | Option Exercise | $5.60 | 932 | 5,219 | 37,685 | Feb 17, 2021, 05:15 PM |
| NEUMANN CLARKE | General Counsel and Secretary | Feb 15, 2021 | Option Exercise | $5.60 | 663 | 3,713 | 52,299 | Feb 17, 2021, 05:11 PM |
| Gianakopoulos George | Senior Vice President of Sales | Feb 15, 2021 | Option Exercise | $5.60 | 377 | 2,111 | 22,279 | Feb 17, 2021, 05:09 PM |
| dEsparbes Eric | Chief Financial Officer | Feb 15, 2021 | Option Exercise | $5.60 | 5,361 | 30,022 | 94,031 | Feb 17, 2021, 05:04 PM |
| Cooper Matthew T | Chief Scientific Officer | Feb 15, 2021 | Option Exercise | $5.60 | 662 | 3,707 | 50,961 | Feb 17, 2021, 05:00 PM |
| Gianakopoulos George | Senior Vice President of Sales | Dec 19, 2020 | Option Exercise | $6.32 | 843 | 5,328 | 22,656 | Dec 22, 2020, 07:26 PM |
| Stylli Harry | Chairman & CEO | Dec 19, 2020 | Option Exercise | $6.32 | 8,615 | 54,447 | 14,608,259 | Dec 22, 2020, 07:23 PM |
| NEUMANN CLARKE | General Counsel and Secretary | Dec 19, 2020 | Option Exercise | $6.32 | 1,726 | 10,908 | 52,962 | Dec 22, 2020, 07:22 PM |
| Shihabi Sami | Chief Commercial Officer | Dec 19, 2020 | Option Exercise | $6.32 | 1,757 | 11,104 | 38,617 | Dec 22, 2020, 07:21 PM |
| dEsparbes Eric | Chief Financial Officer | Dec 19, 2020 | Option Exercise | $6.32 | 1,228 | 7,761 | 99,392 | Dec 22, 2020, 07:19 PM |
| Cooper Matthew T | Chief Scientific Officer | Dec 19, 2020 | Option Exercise | $6.32 | 1,805 | 11,408 | 51,623 | Dec 22, 2020, 07:18 PM |
| Silvestry Damon | Chief Operating Officer | Dec 16, 2020 | Buy | $4.58 | 58,081 | 265,857 | 221,230 | Dec 17, 2020, 04:30 PM |
| Silvestry Damon | Chief Operating Officer | Dec 15, 2020 | Buy | $4.07 | 63,870 | 259,951 | 163,149 | Dec 16, 2020, 04:26 PM |
| Alter Jeffrey D. | Director | Dec 14, 2020 | Buy | $4.85 | 20,000 | 97,000 | 38,335 | Dec 15, 2020, 07:27 PM |
| Athyrium Capital Management, LP | 10% Owner | Dec 07, 2020 | Buy | $3.27 | 4,128,440 | 13,499,999 | 26,991,626 | Dec 09, 2020, 05:35 PM |
| Athyrium Opportunities Fund (A) LP | 10% Owner | Dec 07, 2020 | Buy | $3.27 | 4,128,440 | 13,499,999 | 26,991,626 | Dec 09, 2020, 05:35 PM |
| Stylli Harry | Chairman & CEO | Dec 02, 2020 | Buy | $3.27 | 152,905 | 499,999 | 14,616,874 | Dec 04, 2020, 04:30 PM |
| Cooper Matthew T | Chief Scientific Officer | Sep 03, 2020 | Buy | $8.55 | 9,151 | 78,241 | 53,428 | Sep 04, 2020, 03:50 PM |
| Cooper Matthew T | Chief Scientific Officer | Sep 02, 2020 | Buy | $8.55 | 99 | 846 | 44,277 | Sep 04, 2020, 03:50 PM |
| Stylli Harry | Chairman & CEO | Aug 19, 2020 | Buy | $8.94 | 10,000 | 89,400 | 14,463,969 | Aug 21, 2020, 04:15 PM |
| Athyrium Capital Management, LP | 10% Owner | Jun 23, 2020 | Buy | $15.00 | 3,333,333 | 49,999,995 | 23,303,346 | Jun 25, 2020, 04:25 PM |
| Athyrium Opportunities Fund (A) LP | 10% Owner | Jun 23, 2020 | Buy | $15.00 | 3,333,333 | 49,999,995 | 23,303,346 | Jun 25, 2020, 04:18 PM |
| Stylli Harry | Chairman & CEO | Jun 19, 2020 | Buy | $15.00 | 33,333 | 499,995 | 1,038,635 | Jun 23, 2020, 07:54 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| NEUMANN CLARKE | See Remarks | 08/15/2023 | 113,615 |
| dEsparbes Eric | Chief Financial Officer | 08/15/2023 | 125,669 |
| MOHANTY ADITYA P. | Chief Executive Officer | 08/15/2023 | 370,146 |
| dEsparbes Eric | Chief Financial Officer | 05/15/2023 | 9,403 |
| NEUMANN CLARKE | See Remarks | 05/15/2023 | 7,933 |
| MOHANTY ADITYA P. | Chief Executive Officer | 05/15/2023 | 37,684 |
| NEUMANN CLARKE | See Remarks | 03/15/2023 | 27,348 |
| MOHANTY ADITYA P. | Chief Executive Officer | 03/15/2023 | 56,965 |
| dEsparbes Eric | Chief Financial Officer | 03/15/2023 | 28,713 |
| NEUMANN CLARKE | See Remarks | 02/15/2023 | 291 |
| dEsparbes Eric | Chief Financial Officer | 02/15/2023 | 931 |
| NEUMANN CLARKE | See Remarks | 11/15/2022 | 1,223 |
| MOHANTY ADITYA P. | Chief Executive Officer | 11/15/2022 | 47,269 |
| dEsparbes Eric | Chief Financial Officer | 11/15/2022 | 1,402 |
| NEUMANN CLARKE | See Remarks | 08/15/2022 | 1,409 |
| dEsparbes Eric | Chief Financial Officer | 08/15/2022 | 6,190 |
| Sarna Surbhi | Director | 07/05/2022 | 4,585 |
| NEUMANN CLARKE | See Remarks | 05/15/2022 | 6,229 |
| dEsparbes Eric | Chief Financial Officer | 05/15/2022 | 7,790 |
| dEsparbes Eric | Chief Financial Officer | 02/15/2022 | 9,346 |
| Hashemi Hutan | Chief Compliance Officer | 02/15/2022 | 355 |
| NEUMANN CLARKE | See Remarks | 02/15/2022 | 3,260 |
| NEUMANN CLARKE | See Remarks | 11/15/2021 | 2,609 |
| Hashemi Hutan | Chief Compliance Officer | 11/15/2021 | 2,238 |
| Cooper Matthew T | General Manager, Diagnostics | 11/15/2021 | 2,429 |
| Silvestry Damon | See Remarks | 11/15/2021 | 15,844 |
| NEUMANN CLARKE | See Remarks | 08/15/2021 | 3,878 |
| Silvestry Damon | See Remarks | 08/15/2021 | 2,453 |
| Stylli Harry | Chairman & CEO | 08/15/2021 | 17,156 |
| Hashemi Hutan | Chief Compliance Officer | 08/15/2021 | 262 |
| dEsparbes Eric | Chief Financial Officer | 08/15/2021 | 9,492 |
| Cooper Matthew T | Chief Scientific Officer | 08/15/2021 | 930 |
| Seelye Troy | Chief Information Officer | 08/06/2021 | 45,926 |
| Athyrium Opportunities Fund (A) LP | 10% Owner | 06/01/2021 | 3,626,809 |
| Seelye Troy | Chief Information Officer | 05/15/2021 | 4,543 |
| Hashemi Hutan | Chief Compliance Officer | 05/15/2021 | 163 |
| Silvestry Damon | Chief Operating Officer | 04/15/2021 | 12,552 |
| dEsparbes Eric | Chief Financial Officer | 04/15/2021 | 46,683 |
| Shihabi Sami | Chief Commercial Officer | 03/04/2021 | 10,623 |
| NEUMANN CLARKE | General Counsel and Secretary | 03/04/2021 | 6,334 |
| Gianakopoulos George | Senior Vice President of Sales | 03/04/2021 | 1,985 |
| Cooper Matthew T | Chief Scientific Officer | 03/04/2021 | 6,516 |
| dEsparbes Eric | Chief Financial Officer | 03/04/2021 | 6,512 |
| Stylli Harry | Chairman & CEO | 02/15/2021 | 63,207 |
| Shihabi Sami | Chief Commercial Officer | 02/15/2021 | 5,219 |
| NEUMANN CLARKE | General Counsel and Secretary | 02/15/2021 | 3,713 |
| Gianakopoulos George | Senior Vice President of Sales | 02/15/2021 | 2,111 |
| dEsparbes Eric | Chief Financial Officer | 02/15/2021 | 30,022 |
| Cooper Matthew T | Chief Scientific Officer | 02/15/2021 | 3,707 |
| Gianakopoulos George | Senior Vice President of Sales | 12/19/2020 | 5,328 |
| Stylli Harry | Chairman & CEO | 12/19/2020 | 54,447 |
| NEUMANN CLARKE | General Counsel and Secretary | 12/19/2020 | 10,908 |
| Shihabi Sami | Chief Commercial Officer | 12/19/2020 | 11,104 |
| dEsparbes Eric | Chief Financial Officer | 12/19/2020 | 7,761 |
| Cooper Matthew T | Chief Scientific Officer | 12/19/2020 | 11,408 |
| Silvestry Damon | Chief Operating Officer | 12/16/2020 | 265,857 |
| Silvestry Damon | Chief Operating Officer | 12/15/2020 | 259,951 |
| Alter Jeffrey D. | Director | 12/14/2020 | 97,000 |
| Athyrium Capital Management, LP | 10% Owner | 12/07/2020 | 13,499,999 |
| Athyrium Opportunities Fund (A) LP | 10% Owner | 12/07/2020 | 13,499,999 |
| Stylli Harry | Chairman & CEO | 12/02/2020 | 499,999 |
| Cooper Matthew T | Chief Scientific Officer | 09/03/2020 | 78,241 |
| Cooper Matthew T | Chief Scientific Officer | 09/02/2020 | 846 |
| Stylli Harry | Chairman & CEO | 08/19/2020 | 89,400 |
| Athyrium Capital Management, LP | 10% Owner | 06/23/2020 | 49,999,995 |
| Athyrium Opportunities Fund (A) LP | 10% Owner | 06/23/2020 | 49,999,995 |
| Stylli Harry | Chairman & CEO | 06/19/2020 | 499,995 |
Load More Insider Transactions
FUNDS WITH A POSITION IN BIORA THERAPEUTICS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 93,038 | 0.00001% | 4.45% | Other |
| BLACKROCK INC. | 65,051 | 0% | No change | Other |
CHANGE IN SHARES OUTSTANDING FOR BIORA THERAPEUTICS INC
STOCK BUYBACKS FOR BIORA THERAPEUTICS INC
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
4.98%
1Q
06/30/2023
29.90%
2Q
BUYBACK ANNOUNCEMENT(S) FOR BIORA THERAPEUTICS INC
LOADING...